Quality of Randomized Controlled Trials in the Association of Southeast Asian Nations (ASEAN) - A Systematic Review.

IF 2 4区 医学 Q4 MEDICAL INFORMATICS
Marlinang Diarta Siburian, Sifa Marie-Joelle Muchanga, Antonio Villanueva, Asuka Nagatani, Takuma Kato, Koji Wada, Masamitsu Eitoku, Takeshi Murakami, Narufumi Suganuma
{"title":"Quality of Randomized Controlled Trials in the Association of Southeast Asian Nations (ASEAN) - A Systematic Review.","authors":"Marlinang Diarta Siburian, Sifa Marie-Joelle Muchanga, Antonio Villanueva, Asuka Nagatani, Takuma Kato, Koji Wada, Masamitsu Eitoku, Takeshi Murakami, Narufumi Suganuma","doi":"10.1007/s43441-025-00789-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to assess the quality and characteristics of RCTs in the ASEAN Member States (AMS) during a decade of harmonization efforts.</p><p><strong>Methods: </strong>This study is a systematic review to assess the quality of RCTs conducted in AMS. Studies were included if they were (1) reports of RCTs involving AMS from 2010 to 2021; (2) published in English; and (3) available in full text. Literature searches were conducted in MEDLINE and EMBASE. Study quality was assessed using the Cochrane's risk-of-bias tool and were classified as high- or low-quality. Multiple logistic regression analysis was used to identify characteristics associated with RCT quality.</p><p><strong>Results & discussions: </strong>A total of 51,177 articles were identified, among which 437 studies were eligible for quality assessment. Of the 437 studies, 41.6% were of high-quality. The use of blinding and a higher number of participants (100-1000 and > 1000) contributed positively to study quality (odds ratio (OR): 1.60 [95% confidence interval (CI): 1.05-2.41]; OR: 1.91 [95%CI: 1.24-2.94]; OR: 3.14 [95%CI: 1.22-8.10], respectively). Whereas the use of non-parallel assignment in the type of randomization contributed negatively to study quality (OR: 0.51 [95% CI: 0.26-1.03], P = 0.060). Among the six AMS with a high number of RCTs, two had high-quality studies > 50%, three had slightly more than 40% and one had less than 20%.</p><p><strong>Conclusions: </strong>In the decade of regulatory harmonization, less than half of RCTs in AMS were of high-quality. Large numbers of participants and the use of blinding were associated with high-quality RCTs, while the opposite was true for studies with non-parallel assignment. To improve the quality of RCTs, more training and capacity building of local researchers is needed, with particular attention to study design.</p>","PeriodicalId":23084,"journal":{"name":"Therapeutic innovation & regulatory science","volume":" ","pages":"718-727"},"PeriodicalIF":2.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic innovation & regulatory science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s43441-025-00789-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICAL INFORMATICS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: This study aimed to assess the quality and characteristics of RCTs in the ASEAN Member States (AMS) during a decade of harmonization efforts.

Methods: This study is a systematic review to assess the quality of RCTs conducted in AMS. Studies were included if they were (1) reports of RCTs involving AMS from 2010 to 2021; (2) published in English; and (3) available in full text. Literature searches were conducted in MEDLINE and EMBASE. Study quality was assessed using the Cochrane's risk-of-bias tool and were classified as high- or low-quality. Multiple logistic regression analysis was used to identify characteristics associated with RCT quality.

Results & discussions: A total of 51,177 articles were identified, among which 437 studies were eligible for quality assessment. Of the 437 studies, 41.6% were of high-quality. The use of blinding and a higher number of participants (100-1000 and > 1000) contributed positively to study quality (odds ratio (OR): 1.60 [95% confidence interval (CI): 1.05-2.41]; OR: 1.91 [95%CI: 1.24-2.94]; OR: 3.14 [95%CI: 1.22-8.10], respectively). Whereas the use of non-parallel assignment in the type of randomization contributed negatively to study quality (OR: 0.51 [95% CI: 0.26-1.03], P = 0.060). Among the six AMS with a high number of RCTs, two had high-quality studies > 50%, three had slightly more than 40% and one had less than 20%.

Conclusions: In the decade of regulatory harmonization, less than half of RCTs in AMS were of high-quality. Large numbers of participants and the use of blinding were associated with high-quality RCTs, while the opposite was true for studies with non-parallel assignment. To improve the quality of RCTs, more training and capacity building of local researchers is needed, with particular attention to study design.

东南亚国家联盟(ASEAN)随机对照试验质量的系统评价。
本研究旨在评估东盟成员国(AMS)在十年协调努力期间的随机对照试验的质量和特征。方法:本研究是一项系统评价在AMS中进行的随机对照试验质量的研究。纳入以下研究:(1)2010年至2021年涉及AMS的随机对照试验报告;(二)以英文出版的;(3)提供全文。在MEDLINE和EMBASE中进行文献检索。使用Cochrane的偏倚风险工具评估研究质量,并将其分为高质量和低质量。采用多元逻辑回归分析确定与RCT质量相关的特征。结果与讨论:共纳入51177篇文献,其中437篇符合质量评价标准。在437项研究中,41.6%为高质量研究。采用盲法和较高的受试者人数(100-1000和100-1000)对研究质量有积极影响(优势比(OR): 1.60[95%置信区间(CI): 1.05-2.41];Or: 1.91 [95%ci: 1.24-2.94];OR: 3.14 [95%CI: 1.22-8.10])。然而,在随机化类型中使用非平行分配对研究质量有负面影响(OR: 0.51 [95% CI: 0.26-1.03], P = 0.060)。在6个随机对照试验数量较多的AMS中,2个有50%以上的高质量研究,3个略高于40%,1个低于20%。结论:在监管协调的十年中,AMS中不到一半的rct是高质量的。大量的参与者和使用盲法与高质量的随机对照试验相关,而非平行分配的研究则相反。为了提高随机对照试验的质量,需要对当地研究人员进行更多的培训和能力建设,尤其要注意研究设计。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Therapeutic innovation & regulatory science
Therapeutic innovation & regulatory science MEDICAL INFORMATICS-PHARMACOLOGY & PHARMACY
CiteScore
3.40
自引率
13.30%
发文量
127
期刊介绍: Therapeutic Innovation & Regulatory Science (TIRS) is the official scientific journal of DIA that strives to advance medical product discovery, development, regulation, and use through the publication of peer-reviewed original and review articles, commentaries, and letters to the editor across the spectrum of converting biomedical science into practical solutions to advance human health. The focus areas of the journal are as follows: Biostatistics Clinical Trials Product Development and Innovation Global Perspectives Policy Regulatory Science Product Safety Special Populations
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信